Brian M. Maas
About
Brian M. Maas is a scholar working on Epidemiology, Infectious Diseases and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Brian M. Maas has authored 29 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 11 papers in Infectious Diseases and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Brian M. Maas's work include Respiratory viral infections research (13 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and Pneumonia and Respiratory Infections (5 papers). Brian M. Maas is often cited by papers focused on Respiratory viral infections research (13 papers), SARS-CoV-2 and COVID-19 Research (6 papers) and Pneumonia and Respiratory Infections (5 papers). Brian M. Maas collaborates with scholars based in United States, Japan and Chile. Brian M. Maas's co-authors include Yanguang Cao, Antonios O. Aliprantis, Kalpit A. Vora, Radha Railkar, Luzelena Caro, Brad Roadcap, Andrew W. Lee, Hua Ma, S. Aubrey Stoch and Eseng Lai and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.
In The Last Decade
Brian M. Maas
25 papers receiving 237 citations
Peers
Brian M. Maas
E. Vidal Spain
Xiaowen Zhai China
Gregory J. Walker Australia
M Ardian Australia
Akiko Mizukami Japan
Yong Kek Pang Malaysia
Sven Philip Aries Germany
Amy P. Callear United States
Xiang‐Yan Zhang China
Citations per year, relative to Brian M. Maas Brian M. Maas (= 1×)
peers
E. Vidal
Countries citing papers authored by Brian M. Maas
Since
Specialization
Citations
This map shows the geographic impact of Brian M. Maas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian M. Maas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian M. Maas more than expected).
Fields of papers citing papers by Brian M. Maas
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Brian M. Maas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian M. Maas. The network helps show where Brian M. Maas may publish in the future.
Co-authorship network of co-authors of Brian M. Maas
This figure shows the co-authorship network connecting the top 25 collaborators of Brian M. Maas. A scholar is included among the top collaborators of Brian M. Maas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian M. Maas. Brian M. Maas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Plock, Nele, Jeffrey R. Sachs, Kalpit A. Vora, et al.. (2025). Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease. Communications Medicine. 5(1). 119–119.
2.
Chawla, Akshita, Ruthie Birger, Brian M. Maas, et al.. (2025). Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID ‐19. Clinical and Translational Science. 18(4). e70184–e70184.
3.
Sinha, Anushua, Radha Railkar, Luis A. Castagnini, et al.. (2025). Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemporary Clinical Trials. 157. 107995–107995.
4.
Cheng, Mickie, Alex Mann, Brian M. Maas, et al.. (2025). A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus. Pulmonary Therapy. 11(2). 285–304.
5.
Fiore, Joseph, Yoon Jin, Tycho Heimbach, et al.. (2025). Pharmacokinetics and bioequivalence of a molnupiravir tablet formulation compared with the molnupiravir capsule formulation in healthy adult participants—a randomized, open-label, three-period, crossover study. Antimicrobial Agents and Chemotherapy. 69(3). e0143424–e0143424.
6.
Caraco, Yoseph, Matthew G. Johnson, Brian M. Maas, et al.. (2025). Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study. Clinical Trials. 22(3). 312–324.
7.
Phuah, Jia Yao, Ryan P. Staupe, Yu Cao, et al.. (2024). Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150. The Journal of Infectious Diseases. 231(3). e488–e496.
8.
Duncan, Kelly, Russ P. Carstens, Yoon Jin, et al.. (2024). Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment. Clinical and Translational Science. 17(12). e70073–e70073.
9.
Madhi, Shabir A., Eric A. F. Simões, Radha Railkar, et al.. (2024). A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. The Journal of Infectious Diseases. 231(3). e478–e487.
10.
Phuah, Jia Yao, Brian M. Maas, Aimin Tang, et al.. (2023). Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomedicine & Pharmacotherapy. 169. 115851–115851.
11.
Chawla, Akshita, Ruthie Birger, Hong Wan, et al.. (2023). Factors Influencing COVID ‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes. Clinical Pharmacology & Therapeutics. 113(6). 1337–1345.
12.
Iwamoto, Marian, Kelly Duncan, Tian Zhao, et al.. (2023). Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants. Clinical and Translational Science. 16(10). 1947–1956.
13.
Fujimoto, Katsukuni, Chihiro Hasegawa, Ikuo Aoki, et al.. (2022). A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19. Clinical and Translational Science. 15(11). 2697–2708.
14.
Xu, Weifeng, Brian M. Maas, Brad Roadcap, et al.. (2022). Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis. The AAPS Journal. 24(6). 102–102.
15.
Maas, Brian M., Antonios O. Aliprantis, Kalpit A. Vora, et al.. (2018). 1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development. Open Forum Infectious Diseases. 5(suppl_1). S424–S425.
16.
Chen, Jingxian, Brian M. Maas, Mackenzie L. Cottrell, et al.. (2018). A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. Journal of Pharmacology and Experimental Therapeutics. 367(2). 245–251.
17.
Dumond, Julie B., Stephen A. Greene, Heather Prince, et al.. (2018). Differential Extracellular, but Similar Intracellular, Disposition of two Tenofovir Formulations in the Male Genital Tract. Antiviral Therapy. 24(1). 45–50.
18.
Maas, Brian M., et al.. (2017). Bone Mineral Density to Assess Pediatric Bone Health in Drug Development. Therapeutic Innovation & Regulatory Science. 51(6). 756–760.
19.
Maas, Brian M., Katie R. Mollan, Cynthia Lee, et al.. (2016). Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection. PLoS ONE. 11(12). e0168709–e0168709.
20.
Plewig, Gerd, et al.. (1986). [Remission behavior following low-dose 13-cis-retinoic acid in papulopustular acne].. PubMed. 61(17). 1205–10.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by E. Vidal Breakdown of academic impact, for papers by Xiaowen Zhai Breakdown of academic impact, for papers by Gregory J. Walker Breakdown of academic impact, for papers by M Ardian Breakdown of academic impact, for papers by Akiko Mizukami Breakdown of academic impact, for papers by Yong Kek Pang Breakdown of academic impact, for papers by Sven Philip Aries Breakdown of academic impact, for papers by Amy P. Callear Breakdown of academic impact, for papers by Xiang‐Yan Zhang